Guggenheim Stays Bullish on Cigna (CI) With Updated $318 Price Target

Core Insights - The Cigna Group is recognized as one of the 14 Best US Stocks to Buy for the Long Term [1] - Guggenheim has raised its price target for Cigna to $318 from $309 while maintaining a Buy rating [2] - Cigna reported a 10% year-over-year revenue growth, reaching $69.7 billion in Q3 2025, exceeding analysts' estimates by $3 billion [3] Revenue Growth - The Evernorth Health Services segment, which includes Pharmacy Benefit Services and Specialty and Care Services, was the primary driver of revenue growth [4] - Adjusted revenue from this segment grew by 15%, while adjusted income from operations increased by 1% [4] Strategic Initiatives - Cigna introduced a new pharmacy benefit model aimed at addressing significant challenges in the healthcare industry, focusing on cost reductions and increased transparency [3]